SCHEMBL920762

SCHEMBL920762

Fc1[c]ccc(Oc2ccccc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.48
TSHR P16473 1/20 0.48
MAOB P27338 2/20 0.44
AKR1C3 P42330 1/20 0.40
MAOA P21397 2/20 0.39
NR1H2 P55055 1/20 0.39
BAX Q07812 1/20 0.39
GSTP1 P09211 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MITF O75030 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
GFER P55789 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NLRP1 Q9C000 1/20 0.36
NOD2 Q9HC29 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL919927 0.85 SLC6A2 (0.38) KMT2AALDH1A1MAPT
SCHEMBL919683 0.84 HSPB1 (0.40) LTA4HMEN1KMT2AMITFALDH1A1
SCHEMBL920607 0.82 ALDH1A1 (0.50) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL922603 0.82 AR (0.42) MAOBKMT2ASMN1; SMN2MAPK1HTT
SCHEMBL919676 0.82 SMN1; SMN2 (0.50) MAOBMEN1KMT2AALDH1A1MAPT
SCHEMBL921863 0.81 LTA4H (0.45) LTA4HMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21630265 0.81 LTA4H (0.34) LTA4HMEN1KMT2AMITFALDH1A1
SCHEMBL21630325 0.81 MAPT (0.44) LTA4HTSHRMAOBMAOAMEN1
SCHEMBL921637 0.81 S1PR2 (0.34) LTA4HTSHR
SCHEMBL920492 0.81 TEAD4 (0.44) MEN1KMT2AALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021136219-A1 BTK INHIBITORS DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-07-08 WO claimed
CN-106456652-A Salts and solid forms of BTK inhibitors 普林斯匹亚生物制药公司 2017-02-22 CN claimed
US-20090118286-A1 Heterobicyclic Acrylamides BAYER CROPSCIENCE AG (DE) 2009-05-07 US claimed
CN-101171255-A Heterobicyclic acrylamides BAYER CROPSCIENCE AG (DE) 2008-04-30 CN claimed
EP-1858899-A1 HETEROBICYCLIC ACRYLAMIDES Bayer CropScience AG (DE) 2007-11-28 EP claimed
WO-2006094666-A1 HETEROBICYCLIC ACRYLAMIDES BAYER CROPSCIENCE AG (DE) 2006-09-14 WO claimed
EP-3912980-A1 CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR Minghui Pharmaceutical (Shanghai) Limited (CN) 2021-11-24 EP disclosed
WO-2021136219-A1 BTK INHIBITORS DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-07-08 WO disclosed
US-20200031778-A1 NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-01-30 US disclosed
EP-3519389-A1 NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES Bayer CropScience Aktiengesellschaft (DE) 2019-08-07 EP disclosed
WO-2018103060-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2018-06-14 WO disclosed
WO-2018103058-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2018-06-14 WO disclosed
WO-2018060091-A1 NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-04-05 WO disclosed
WO-2006094666-A1 HETEROBICYCLIC ACRYLAMIDES BAYER CROPSCIENCE AG (DE) 2006-09-14 WO disclosed
CN-1058841-C Fungicidal oxazolidinones DU PONT (US) 2000-11-29 CN disclosed
CN-1187814-A (hetero) aryloxy-, -thio-and-aminocrotonates, preparation and use thereof BASF AG (DE) 1998-07-15 CN disclosed
CN-1161687-A Phenylacetic acid alkyl esters BASF AG (DE) 1997-10-08 CN disclosed
CN-1028143-C Oxazolidinone sterilization composition DU PONT (US) 1995-04-12 CN disclosed
CN-1096157-A Antifungal De oxazolidone DU PONT (US) 1994-12-14 CN disclosed
CN-1047079-A FUNGICIDAL OXAZOLIDINONES DU PONT (US) 1990-11-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118286-A1 Heterobicyclic Acrylamides CCNB1, C3AR1, CCNA2 LTA4H 1390/4885TSHR 982/4885MAOB 1732/4885
US-20200031778-A1 NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES IPMK, PIP5K1B, PIP5K1C LTA4H 3800/4885TSHR 3409/4885MAOB 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.